BMS and bluebird bio gain FDA approval for multiple myeloma therapy

The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb (BMS) and bluebird bio’s BCMA-targeting CAR T cell therapy Abecma – previously known as ide-cel – for the

J&J’s MS drug ponesimod receives approval in the US

In March 2020, the FDA also approved Bristol Myers Squibb’s (BMS) own S1P receptor modulator Zeposia ( ozanimod) for the treatment of adults with relapsing forms of MS.

FDA accepts BMS’ investigational cardiovascular drug mavacamten for review

The US Food and Drug Administration (FDA) is set to review Bristol Myers Squibb’s (BMS) investigational candidate mavacamten for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

FDA advisory committee to review oncology accelerated approvals

The Oncology Drugs Advisory Committee will meet to review six indications for Roche’s Tecentriq (atezolizumab), Merck and Co’s Keytruda (pembrolizumab) and Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]